Benign Prostatic Hyperplasia (BPH)



The Influence of Benign Prostatic Hyperplasia on Bladder Function


Condition:   Prostatic Hyperplasia
Intervention:  
Sponsor:   Xiangfu Zhou
Recruiting - verified March 2017


Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Active, not recruiting - verified April 2017


Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia


Conditions:   Prostatic Hyperplasia, Benign;   Prostatic Hyperplasia With Urinary Obstruction With Lower Urinary Tract Symptoms
Intervention:   Device: Embosphere microparticles for prostate artery embolization
Sponsor:   University of California, San Diego
Recruiting - verified May 2017


Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prostate Artery Embolization
Sponsors:   Northwestern University;   BTG International Inc.
Not yet recruiting - verified May 2017


Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: Prostate Artery Embolization
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified October 2016


Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Active, not recruiting - verified April 2017


Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Device: Embosphere® (Prostatic Arteries Embolization);   Drug: Drug therapy
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Ministry of Health, France
Recruiting - verified April 2017


Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams


Condition:   Prostatic Hyperplasia
Intervention:   Device: Embosphere Microspheres
Sponsor:   South Florida Medical Imaging, PA
Recruiting - verified February 2017


A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: talaporfin sodium;   Drug: Saline;   Device: Drug Activator 100 J/cm;   Device: Drug Activator 200 J/cm
Sponsors:   Light Sciences Oncology;   Mundipharma Research Limited
Active, not recruiting - verified January 2017


AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Completed - verified May 2017


Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Drug: Embozene Microspheres
Sponsors:   Jena University Hospital;   Boston Scientific Corporation
Active, not recruiting - verified April 2016


Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: Microspheres
Sponsor:   University of North Carolina, Chapel Hill
Completed - verified May 2017


Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia


Conditions:   Nocturia;   Benign Prostatic Hyperplasia
Interventions:   Drug: Silodosin;   Other: Laboratory tests;   Other: 3-days voiding diary;   Other: 12 weeks
Sponsor:   JW Pharmaceutical
Completed - verified March 2017


Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia


Condition:   Prostatic Hyperplasia
Interventions:   Drug: Dutasteride 0.5mg capsules;   Drug: Dutasteride placebo capsules;   Drug: Tamsulosin 0.2mg tablets;   Drug: Disintegrating placebo tamsulosin tablet
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prostate Artery Embolization
Sponsor:   Northwestern University
Recruiting - verified March 2017


Prostate Embolization for Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Procedure: Prostatic Embolization;   Drug: Embosphere® Microspheres
Sponsor:   James B. Spies, MD
Recruiting - verified July 2016


Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Vortx Rx - Histotripsy BPH Device
Sponsor:   HistoSonics, Inc.
Active, not recruiting - verified February 2017


Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Device: Embosphere Microspheres;   Procedure: TURP
Sponsor:   Merit Medical Systems, Inc.
Recruiting - verified October 2015


Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Afalaza;   Drug: Placebo
Sponsor:   Materia Medica Holding
Completed - verified October 2016


Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia (BPH)
Interventions:   Device: Greenlight XPS Laser;   Device: BiVAP Saline Vaporization of the prostate
Sponsors:   Brooklyn Urology Research Group;   American Medical Systems;   Richard Wolf Medical Instruments Corporation (RWMIC)
Completed - verified January 2017


Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Early combination therapy;   Drug: Delayed combination therapy
Sponsor:   GlaxoSmithKline
Completed - verified May 2017


Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: S-equol;   Drug: Placebo
Sponsor:   Ausio Pharmaceuticals, LLC
Completed - verified April 2017


A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: placebo;   Drug: sildenafil
Sponsor:   Pfizer
Completed - verified March 2017


A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: MK0906, finasteride / Duration of Treatment: 48 weeks;   Drug: Comparator: placebo / Duration of Treatment: 48 weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017


Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment


Condition:   Prostatic Hyperplasia
Interventions:   Drug: dutasteride 0.5mg once daily for 4 years;   Drug: tamsulosin 0.4mg once daily for 4 years
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Refine Your Search Advanced Search